Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 329

1.
2.

Benefit of hospital pharmacy intervention on the current status of dry powder inhaler technique in patients with asthma and COPD: a study from the Central Development Region, Nepal.

Poudel RS, Piryani RM, Shrestha S, Prajapati A.

Integr Pharm Res Pract. 2016 Dec 20;6:7-13. doi: 10.2147/IPRP.S119202. eCollection 2017.

3.

Estimation of inhalation flow profile using audio-based methods to assess inhaler medication adherence.

Taylor TE, Lacalle Muls H, Costello RW, Reilly RB.

PLoS One. 2018 Jan 18;13(1):e0191330. doi: 10.1371/journal.pone.0191330. eCollection 2018.

4.

Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes.

Usmani OS, Lavorini F, Marshall J, Dunlop WCN, Heron L, Farrington E, Dekhuijzen R.

Respir Res. 2018 Jan 16;19(1):10. doi: 10.1186/s12931-017-0710-y. Review.

5.

The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease.

Halpin DMG.

Tuberc Respir Dis (Seoul). 2018 Jan;81(1):13-18. doi: 10.4046/trd.2017.0098. Review.

6.

Identification of inhaler technique errors with a routine procedure in Portuguese community pharmacy.

Castel-Branco MM, Fontes A, Figueiredo IV.

Pharm Pract (Granada). 2017 Oct-Dec;15(4):1072. doi: 10.18549/PharmPract.2017.04.1072. Epub 2017 Dec 18.

7.

Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.

Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.

Adv Ther. 2018 Jan;35(1):56-71. doi: 10.1007/s12325-017-0650-4. Epub 2018 Jan 8.

8.

The current state and provisions for elderly patients with asthma.

Iwanaga T, Sano H, Tohda Y.

J Gen Fam Med. 2017 May 23;18(3):102-107. doi: 10.1002/jgf2.6. eCollection 2017 Jun.

9.

Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.

Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.

Adv Ther. 2017 Nov;34(11):2518-2533. doi: 10.1007/s12325-017-0626-4. Epub 2017 Nov 1.

11.

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol.

Koch A, Watz H, Maleki-Yazdi MR, Bothner U, Tetzlaff K, Voß F, McGarvey L.

NPJ Prim Care Respir Med. 2017 Oct 23;27(1):60. doi: 10.1038/s41533-017-0059-1.

12.

Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat.

Davis KH, Su J, González JM, Trudeau JJ, Nelson LM, Hauber B, Hollis KA.

Health Qual Life Outcomes. 2017 Oct 16;15(1):201. doi: 10.1186/s12955-017-0780-z.

13.

The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.

Albertson TE, Murin S, Sutter ME, Chenoweth JA.

Pragmat Obs Res. 2017 Sep 20;8:175-181. doi: 10.2147/POR.S144157. eCollection 2017. Review.

14.

Short-term Evaluation of a Comprehensive Education Program Including Inhaler Training and Disease Management on Chronic Obstructive Pulmonary Disease.

Yoo KH, Chung WY, Park JH, Hwang SC, Kim TE, Oh MJ, Kang DR, Rhee CK, Yoon HK, Kim TH, Kim DK, Park YB, Kim SH, Yum HK.

Tuberc Respir Dis (Seoul). 2017 Oct;80(4):377-384. doi: 10.4046/trd.2017.0041. Epub 2017 Sep 1.

15.

Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.

Ismaila AS, Birk R, Shah D, Zhang S, Brealey N, Risebrough NA, Tabberer M, Zhu CQ, Lipson DA.

Adv Ther. 2017 Sep;34(9):2163-2172. doi: 10.1007/s12325-017-0604-x. Epub 2017 Sep 5.

16.

The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.

Jones R, Martin J, Thomas V, Skinner D, Marshall J, Stagno d'Alcontres M, Price D.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 17;12:2445-2454. doi: 10.2147/COPD.S141409. eCollection 2017.

17.

Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation.

Sharma G, Mahler DA, Mayorga VM, Deering KL, Harshaw O, Ganapathy V.

Chronic Obstr Pulm Dis. 2017 Jul 15;4(3):217-224. doi: 10.15326/jcopdf.4.3.2017.0183.

18.

Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.

Sethi S, Fogarty C, Hanania NA, Martinez FJ, Rennard S, Fries M, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Dwivedi S, Reisner C.

Chronic Obstr Pulm Dis. 2016 Nov 17;4(1):21-33. doi: 10.15326/jcopdf.4.1.2016.0158. Erratum in: Chronic Obstr Pulm Dis. 2017 Apr 15;4(3):258.

19.

Factors affecting satisfaction with education program for chronic airway disease in primary care settings.

Kim A, Hwang YI, Kim JH, Jang SH, Park S, Park JY, Jung KS, Yoo KH, Park YB, Yoon HK, Rhee CK, Kim DK, Yum HK.

J Thorac Dis. 2017 Jul;9(7):1911-1918. doi: 10.21037/jtd.2017.06.01.

20.

Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.

Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S.

Respir Res. 2017 Aug 21;18(1):158. doi: 10.1186/s12931-017-0638-2. No abstract available.

Supplemental Content

Loading ...
Support Center